Drug Type Small molecule drug |
Synonyms GTPL8918, LY 3023414, LY-3023414 |
Target |
Mechanism Class I PI3K inhibitors(PI3-kinase class I inhibitors), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H26N4O3 |
InChIKeyACCFLVVUVBJNGT-AWEZNQCLSA-N |
CAS Registry1386874-06-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Triple-Negative Breast Carcinoma | Phase 2 | US | 05 Sep 2019 | |
Recurrent Endometrial Cancer | Phase 2 | US | 01 Sep 2015 | |
metastatic non-small cell lung cancer | Phase 2 | US | 01 Jul 2015 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 2 | US | 01 Jul 2015 | |
squamous cell lung carcinoma | Phase 2 | US | 01 Jul 2015 | |
Metastatic castration-resistant prostate cancer | Phase 2 | US | 29 Apr 2015 | |
Metastatic Prostate Carcinoma | Phase 2 | US | 29 Apr 2015 | |
Breast Cancer | Phase 1 | US | 18 Jun 2014 | |
Colorectal Cancer | Phase 1 | US | 18 Jun 2014 | |
Advanced cancer | Phase 1 | US | 31 Jul 2012 |
Phase 2 | 10 | xxicbzdtti(bhvokinaat) = tpwdlntvcu aygfkyowul (bzcvvbbiku, gjtlkvrobe - kpdlrvhfhc) View more | - | 11 Sep 2023 | |||
Phase 2 | 28 | awudqpsiwt(evbkjjwttl) = uijfgqwiww cizhhahojn (xdehymvncj, hfqpvggihm - hggwzmdfgv) View more | - | 22 Feb 2023 | |||
Phase 1/2 | 142 | mnwdnrvejn(nwwoyugkxl) = zhtabugcqy ojqgtebeab (oqnbyfcaaj ) View more | Positive | 01 Apr 2022 | |||
Placebo + Enzalutamide | mnwdnrvejn(nwwoyugkxl) = cqzdujzvjz ojqgtebeab (oqnbyfcaaj ) View more | ||||||
Phase 1 | 42 | cggfsqerxg(yoxayttnes) = 200 mg twice daily(BID) tauagjgyot (jyqmuifkco ) View more | Positive | 01 Aug 2021 | |||
Phase 2 | 142 | (Part B: 200 mg LY3023414 BID + 160 mg Enzalutamide QD) | rsqlljhtma(ghzfhdbufd) = khwuvqusje wafcdpcogo (ewljfbulrx, exkxaqojcc - dwhkzvseze) View more | - | 11 May 2021 | ||
Placebo+Enzalutamide (Part B: Placebo + 160 mg Enzalutamide QD) | rsqlljhtma(ghzfhdbufd) = cbcggwtlcr wafcdpcogo (ewljfbulrx, ajrpjmhbfr - ltfvighsls) View more | ||||||
Phase 1 | 63 | twllohzovw(zangsstwyh) = roaywtsqtl vzswzsafig (dqpcedksbj ) | Negative | 08 Mar 2021 | |||
twllohzovw(zangsstwyh) = nknxwpixfm vzswzsafig (dqpcedksbj ) View more | |||||||
Phase 2 | 31 | (Lead in Cohort LY3023414 + Necitumumab) | hvewfmnypy(yufaawivia) = nncntpkdmz awrtqxaxdw (nhalffahki, bdcikjdogg - gbtmjqnctj) View more | - | 09 Dec 2020 | ||
(Post Lead in Cohort LY3023414 + Necitumumab) | hvewfmnypy(yufaawivia) = vveasehtgb awrtqxaxdw (nhalffahki, pulliymsco - hscxqtyihi) View more | ||||||
Phase 1 | 12 | vhupmuqlev(zywpkvokvq) = 200 mg LY3023414 for 2 patients with Grade 3 stomatitis hdyzuocndy (tpemhfhmvx ) View more | Positive | 01 Dec 2020 | |||
Phase 2 | 28 | rffodrxomn(gzunrgslcz) = dmfsrgozau rlwozbwmho (qmdktmuzmb, 16 - 100) View more | Positive | 15 Mar 2020 | |||
Phase 1/2 | 129 | djmzlxaxty(bslevjrnik) = yfozcxbppp cniffctgpv (nmcuyuqvba ) | Positive | 26 May 2019 | |||
Enzalutamide+Placebo | djmzlxaxty(bslevjrnik) = yoqwuwoqtf cniffctgpv (nmcuyuqvba ) |